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and has poor transplant outcome with a high TRM, a lower EFS
and a lower OS.
3. Group 2 (0.30- 0.85  108/kg) had the best overall engraft-
ment (both ANC and PLT) of close to 80%. TRM was lowest in
this group at 13% but the rate of relapse was higher than the other
groups.
4. Group 3 (0.86- 2.83  108/kg) received higher than the
median MNC cell dose. Compared to Group 2 though this group
shows a lower engraftment it shows comparable EFS. This group
shows that a higher cell dose results in higher TRM (8 of 9
patients) and fewer relapse (4%).
Transplant Outcome
MNC dose group
(x108/kg
Overall
(0.08- 2.83)
(1)
<0.29
(2)
0.30- 0.85
(3)
> 0.86
n 92 19 46 27
ANC engraftment 63; 68.5% 10; 52.6% 38; 79.2% 15; 55.6%
PLT engraftment 58; 63% 10; 52.6% 36; 78.3% 12; 44.4%
Days to ANC 24 36 26 18
Days to PLT 44 56 46 34
TRM 22; 23.9% 8; 42% 6; 13% 8; 29.6%
Relapse 13; 14.1% 3; 15.8% 9; 19.6% 1; 3.7%
EFS 57; 62% 8; 34.8% 31; 67.4% 18; 66.7%
OS (days) 706 326 1396 603
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGI-
CAL DISEASES AT YEDITEPE UNIVERSITY HOSPITAL
Yirmibescik, S.1, Senkal, V.1, Kalayci, G.1, Aktas, S.1, Aydin, D.1,
Sonmezoglu, M.1, Kocagoz, S.1, Oyan, B.1, Koc, Y.1 1Stem Cell Trans-
plant Unit, Yeditepe University Hospital, Istanbul, Turkey.
Stem cell transplantation(SCT) is an effective treatment modality
in hematological malignancies. SCT Unit at Yeditepe University
Hospital(CIC-919) was activated in October 2005 and accredited
for unrelated SCT by EBMT in April 2006. Until September 2006,
13 autologous and 17 allogeneic (4 unrelated) SCT have been
performed. Diagnosis of patients who underwent auto-SCT con-
sisted of HL(n6), NHL(n4) and myeloma (MM, n3). Patients
undergoing allo-SCT had HL(n2), NHL(n2), MM(n3),
CML(n3), CML-BT(n3), AML(n2), ALL(n1), and Thalas-
semia(n1). Median age was 38,5 (20-65) years and mean time
from diagnosis to transplant was 2,3 years. Patients received a
mean number of 8 (2-18) salvage regimens prior to transplantation.
All patients engrafted and median engraftment period was 11
(8-14) days. Transplantation related mortality(TRM) was not ob-
served during the ﬁrst 100 days and follow-up. Median follow-up
period was 5,4 (1-10,5) months. During follow-up, 5 patients
(16%) relapsed and 2 patients died (6%). Of 28 (94%) surviving
patients, 24 (80%) are in CR. All patients (100%) were alive
following auto-SCT at day 100, only one patient with myeloma
died due to relapse at 9 months. In the allo-SCT group, 16 (94%)
of patients were alive at day 100, only one patient died due to
relapse of CML-BT. Post-transplant complications were CMV
viremia(n9), CMV colitis(n3), sinusoidal occlusion syn-
drome(n1), BK viremia and hemorrhagic cystitis(n2), renal
failure(n1). Reversible blindness due to hypophyseal tumor apo-
plexy in a patient at day 11 was successfully corrected by neuro-
surgery. Grade II- III acute GVHD was observed in 8 pa-
tients(47%). All patients with acute GVHD were successfully
treated without mortality. A patient with refractory ALL associated
with CNS and eye involvement achieved complete remission fol-
lowing allo-SCT combined with modulated radiotherapy (IMRT).
All 4 patients (100%) who underwent unrelated-SCT following
autologous transplantation complicated with relapsed-refractory
disease are alive and 3 were in CR at day 100 (2 HL,1 NHL). Of
7 patients undergoing allo-SCT as a second transplant, 6 (85%) are
alive; in this group, only one patient with MM (15%) died due to
relapse. The high survival rate (94%) achieved following autolo-
gous and/or allogeneic SCT including unrelated transplants, low
TRM (0%) and the high remission rate (80%) may be related to
team approach, 24-hour patient follow-up, and effective manage-
ment of acute GVHD.
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VALIDATION OF THE HEMATOPOIETIC CELL TRANSPLANTATION-CO-
MORBIDITY INDEX (HCT-CI) FOR NON-RELAPSE MORTALITY (NRM)
AND SURVIVAL AFTER MATCHED UNRELATED DONOR SCT
Kovacsovics, T.1,2, Hayes-Lattin, B.1,2, Riegert, K.1, Subbiah, N.1,
Curtin, P.T.1,2, Leis, J.F.1,2, Mauro, M.M.1,2, Epner, E.E.1,2,
Fleming, W.H.1,2, Meyers, G.M.1,2, Deininger, M.W.1,2, Dunn, A.1,
Maziarz, R.T.1,2 1Center for Hematological Malignancies, OHSU,
Portland, OR; 2Oregon Cancer Institute, Portland, OR.
Background: The HCT-CI is a recently developed comorbidity
score which has been adapted to hematopoietic stem cell trans-
plantation, with higher scores associated to worse outcomes (Blood
2005;106:2912) . We determined the HCT-CI score in a cohort of
patients who underwent conventional MUD transplantation in a
single arm, single institution trial assessing efﬁcacy of a 3-drug
combination of cyclosporine, methotrexate and prednisone for
GVHD prophylaxis from 1996-2005.
Methods: The analysis included all patients undergoing MUD
transplant who received GVHD prophylaxis with cyclosporine 2
mg/kg iv BID from day -2, methotrexate 15 mg/m2 iv on day 1
and 10 mg/m2 iv on days3 and6, and methylprednisolone 0.25
mg/kg iv BID beginning on day 7 and tapering at day 28.
Patients were stratiﬁed by disease risk per CIBMTR classiﬁcation.
The comorbidities were obtained by retrospective chart review and
scored according to the HCT-CI score.
Results: 133 patients received the 3 drug-regimen, including 26
% with low-, 36 % with intermediate- and 38 % with high-risk
disease. Diagnoses included acute leukemia in 50%, MDS in 9.8%,
CML in 16.5%, lymphoma in 18.1%, multiple myeloma in 3.0%.
52 % were older than 40. Source of stem cells was PBSC in 47.4%,
marrow in 51.9%. and both in 0.8%. Among the 133 patients,
22%, 31% and 47% had HCT-CI scores of 0 vs 1-2 vs 3,
respectively. Overall NRM was 26.3% and 36.8%, at 3 months and
1 year, respectively. Three and 12 month NRM was 13.3%, 14.6
and 40.3% and 30%, 22% and 50% among patients with scores of
of 0 vs 1-2 vs 3, respectively. HR rates for 3 month NRM were
1.10 and 3.7 for HCT-CI scores 1-2 and 3. Kaplan-Meier as-
sessment showed 42.1% 5 year OS for the whole cohort. OS of
60%, 48.% and 28.1% were observed in patients with scores of of
0 vs 1-2 vs 3, respectively (p  0.05). No statistically signiﬁcant
differences in OS were observed between low-, intermediate- and
high-risk CIBMTR disease groups.
Conclusion: HCT-CI was a powerful predictor of 3 and 12
month NRM, as well as of 5 year OS in this cohort of MUD
patients. It will be useful for patient stratiﬁcation in clinical trials
and for treatment allocation.
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SYNGENEIC STEM CELL TRANSPLANTATION FOR APLASTIC ANEMIA IN
AN HIV PATIENT
Longoni, H.O.1, Binaghi, M.A.1, Kohan, A.I.1, Lasala, M.B.1,
Banchieri, A.V.1, Minissale, C.J.1, Plana, J.L.1, Velicche, A.F.1,
Christin, M.P.1, Corach, D.2, Maissonnave, V.1, Calahonra, R.1 1Hos-
pital de Clinicas Jose´ de San Martı´n; University of Buenos Aires, Buenos
Aires, Argentina; 2Facultad de Farmacia y Bioquı´mica; University of
Buenos Aires, Buenos Aires, Argentina.
Allogeneic hematopoietic stem cell transplantation from HLA
identical siblings is an effective treatment for aplastic anemia in
young patients. Heavily transfused patiens have shown an increased
risk of graft rejection requiring a more intensive immunosuppres-
sive conditioning. Usually a combination of cyclophosphamide
(Cy) with total body irradiation (TBI) or more recently with
antithimocyte globuline (ATG) is used.
We report a 32 year old patient with haemorragic manifestations,
haemodynamic instability and pancytopenia, admitted to the Hos-
pital in February 2005. Bone marrow biopsy performed, conﬁrmed
the diagnosis of aplastic anemia, Human Immunodeﬁciency Virus
(HIV) seropositivity was assessed by 2 different methods. No other
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etiologic agent was found, so it was considered that AA was sec-
ondary to HIV. Treatment was initiated with D4T (Stavudine),
3TC (Lamivudine) and Efavirenz achieving undetectable viral load
and increasing CD4 count. Patient also received Erythropoietin
(EPO) and granulocyte-colony stimulating factors (G-CSF) show-
ing an increased number of white blood cells (WBC) but continued
with high transfusional requeirment. We had to stop treatment in
October because of liver failure and lactic acidosis. In November
we changed Stavudine for Tenofovir and reiniciated treatment.
Viral load was always undetectable and CD4 count was  500
cells/ul. However megakaryocytopoiesis and erythropoiesis did not
respond, requiring many transfusions. Coombs Direct Test (CDT)
and Coombs Indirec Test (CIT) were positive.He showed an
immunohaematologic proﬁle with 1 autoantibody (Anti-e) and 3
alloantibodies (Anti-Jka, Anti-Lua, Anti-Cw).
As he had an identical twin, he was submitted to a syngeneic
BMT. Although he was heavily transfused (421 Units ), we did not
want to increase immunosuppression so as not to have viral reac-
tivation. The conditioning regimen consisted of Cy 50 mg/kg/qd x
4, and in order to lower the risk of engrafment failure, peripheral
blood stem cells were used to maximize the number of donor cells
infused (11  106 CD34 cells/kg). At the transplantation the
patient was in high-risk. The antiretroviral treatment was not
discontinued. No graft versus host disease (GVHD) proﬁlaxis was
needed. Neutrophils and platelets engrafted at day 11.
After 10 months of transplantation he continues in complete
haematologic remission. Serum antibodies, CDT and CIT are
negative.Viral load remains undetectable (b-DNA).
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ABSOLUTE CHIMERISM AS A TOOL IN MONITORING IMMINENT AND
MANIFEST GRAFT REJECTION AFTER HEMATOPOIETIC CELL TRANS-
PLANTATION WITH NONMYELOABLATIVE CONDITIONING
Masmas, T.N.1, Petersen, S.L.1, Madsen, H.O.2, Ryder, L.P.2,
Svejgaard, A.2, Andersen, P.2, Dickmeiss, E.2, Vindelov, L.L.1 1Alloge-
neic Hematopoietic Cell Transplantation Laboratory, Department of
Hematology, Rigshospitalet, Copenhagen, Denmark; 2Department of
Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Graft rejection after hematopoietic cell transplantation (HCT)
with nonmyeloablative conditioning is a rare event and a serious
clinical problem. Manifest (N8) and imminent rejection (N4)
in a cohort of 98 consecutive patients with hematological malig-
nancies were analyzed. The patients were conditioned with ﬂu-
darabine 30 mg/m2 and 2 Gy of total body irradiation and trans-
planted with peripheral blood stem cells. Intervention aiming at
reversing imminent rejection with donor lymphocyte infusion
(DLI) alone or preceded by immunosuppression with pentostatin
was attempted with highly variable results. Chimerism analysis is
the standard method to monitor engraftment and rejection. In the
present report we have evaluated the product of absolute T cell
counts and chimerism, which we have termed absolute chimerism,
for monitoring patients with manifest or imminent rejection. The
results suggest that recipient T cell counts  donor T cell counts
and increasing recipient T cells post-transplant are risk factors for
rejection. Peaks of absolute recipient CD4 and/or CD8 T cell
counts were seen in relation to rejection and peaks of donor CD4
and/or CD8 T cells were seen in connection with acute graft-
versus-host disease. Furthermore absolute chimerism plots in some
cases clearly indicate the time-interval where disappearance of
recipient T cells takes place. These ﬁndings may be of importance
for understanding the cellular mechanisms underlying alloreactiv-
ity. Absolute chimerism plots point to a variable immunosuppres-
sive effect of pentostatin on recipient T cells as explanation for
pentostatin/DLI-failure in reversing rejection. We conclude that
absolute chimerism plots can contribute signiﬁcant new informa-
tion of value for routine monitoring of patients with mixed chi-
merism as well as for research purposes. Following rejection pa-
tients are at risk of dying from infections and progression/relapse
of their malignancy. Retransplantation is feasible and well tolerated
after HCT with nonmyeloablative conditioning. In patients with
imminent graft rejection retransplantation is an attractive alterna-
tive to DLI or immunosuppression/DLI.
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AN IMPROVED METHOD FOR ENGRAFTMENT MONITORING USING
REAL-TIME PCR
McLaughlin, I.J.1, Bost, D.A.1, Mountain, J.L.2, McGinnis, M.D.1,
Krausa, P.1 1Atria Genetics, South San Francisco, CA; 2Department of
Anthropological Sciences and Department of Genetics, Stanford Univer-
sity, Stanford, CA.
The commonly used engraftment monitoring method of short
tandem repeat (STR) ampliﬁcation following allogeneic hemato-
poietic stem cell transplantation (HSCT) is hampered by several
shortcomings affecting sensitivity, accuracy, reproducibility, and
results interpretation. In an effort to provide a better solution, we
have developed a truly quantitative, real-time PCR method. Real-
time PCR technology is ideally suited for this application because
it is highly sensitive and quantitatively much more accurate and
precise than STR analysis. It is not affected by problems inherent
to STR ampliﬁcation and analysis such as plateau bias, preferential
allele ampliﬁcation, and stutter artifacts. With our method,
genomic mixtures are easily resolved, and analysis is straightfor-
ward and automatable. Success and maintenance of allogeneic
HSCT may be enhanced with such an improved engraftment
monitoring method.
We have developed a panel of non-repetitive polymorphic mark-
ers, with representatives on all chromosomes, useful for identifying
differences between recipient and donor pairs. Our statistical anal-
yses given allele frequencies in multiple human populations dem-
onstrate that with relatively high minor allele frequencies, a limited
panel of markers can be assembled which would have high prob-
ability of providing informative markers that could distinguish
HLA-matched individuals. The testing process ﬁrst requires that
the donor and recipient genomic DNA be screened in order to
identify informative markers between the two genomes. Once
deﬁned, these markers are used post-transplant to quantify the
relative percentage of recipient genetic material in the donor back-
ground. Compared to the current STR assays, our method shows
a greater than 100-fold increase in sensitivity with excellent accu-
racy and precision at concentrations as low as 0.01% recipient in a
background of 99.99% donor DNA. Given the reproducibility of
results and ease of data analysis, this approach provides the means
for standardization within a testing lab as well as between testing
centers, which cannot be accomplished with homebrew and off-
label methods such as STR analysis. From a clinical perspective,
improved sensitivity, accuracy, and precision provide the potential
to detect disease relapse or transplant rejection at a much earlier
stage. This information may be useful for improving decisions
related to maintenance treatments such as GVHD prophylaxis
and/or donor lymphocyte infusion.
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CHARACTERISTICS OF TWO CONDITIONING REGIMENS CYCLOPHOS-
PHAMIDE PLUS ANTITHYMOCYTE GLOBULIN VERSUS CYCLOPHOSPH-
AMIDE PLUS BUSULFAN IN ALLOGENEIC STEM CELL TRANSPLANTA-
TION FOR SEVERE APLASTIC ANEMIA
Ommati, L.V.M.1,2, Silva, A.P.1, Silva, L.P.1,2, Faria, J.R.2,
Chaufaille, M.d.L.F.1, Oliveira, J.S.P.1,2 1Universidade Federal de Sa˜o
Paulo - UNIFESP, Sa˜o Paulo, Brazil; 2Hospital Santa Marcelina, Sa˜o
Paulo, Brazil.
We report a retrospective study of the clinical features and
outcome for 32 allogeneic stem cell transplants (AlloSCT) from
HLA-matched sibling donors in severe aplastic anemia condi-
tioned with 200 mg/kg of cyclophosphamide plus 90 mg/kg of
horse antithymocyte globulin (ATG) in 17 patients and 120 mg/kg
of cyclophosphamide plus 12 mg/kg of busulfan (Bu) in 15 patients,
at Hospital Sa˜o Paulo and Hospital Santa Marcelina, from No-
vember 1993 to August 2003. Considering high cost of ATG and
the difﬁculty to obtain it for the majority of our centers, the
objective was to compare clinical variables as age, sex, engraftment,
interval of time from diagnosis to AlloSCT, number infused of
total nuclear cells, previous transfusions, occurrence of acute and
chronic GVHD, infections, acute and late graft rejection and
overall survival, between these two conditioning regimens. We
analyzed the long-term hematopoietic chimerism by FISH, using a
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